B cells as a therapeutic target in autoimmune disease
Depleting B cells with anti-CD20 monoclonal antibodies emerges as a new therapeutic strategy in autoimmune diseases. Preliminary clinical studies suggest therapeutic benefits in patients with classic autoantibody-mediated syndromes, such as autoimmune cytopenias. Treatment responses in rheumatoid ar...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2003
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165047/ |